Sibel Ozdemir | Pharmacology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Sibel Ozdemir — Yunus Emre State Hospital, Turkey

Sibel Ozdemir
Affiliation Yunus Emre State Hospital
Country Turkey
Scopus ID 60749146700
Subject Area Pharmacology
Event Health Scientists Awards
ORCID 0009-0003-4671-0964

Sibel Ozdemir is a researcher associated with Yunus Emre State Hospital whose recent scholarly work connects neurology with pharmacological investigation. Published studies have examined antiseizure medicines, experimental seizure models, medication combinations, and potential interactions involving clopidogrel, valproic acid, and levetiracetam. [1] [2]

Abstract

Sibel Ozdemir is a researcher affiliated with Yunus Emre State Hospital in Turkey whose documented work addresses pharmacology, neurology, and experimental seizure research. Her recent publications examine interactions between antiplatelet and antiseizure medicines and pharmacological effects in experimental models. This profile summarizes her research themes, publications, and recognition context in research.

Keywords

Epilepsy, valproic acid, levetiracetam, clopidogrel, pentylenetetrazol, freezing behavior, antiseizure medicines, anticonvulsant efficacy, experimental seizure models, behavioral effects, drug interactions, neurology, pharmacology, and clinical pharmacology. These terms reflect the themes identified in her recent research publications. [1] [2]

Introduction

Sibel Ozdemir is affiliated with the Department of Neurology at Yunus Emre State Hospital, Eskişehir, Türkiye. Her recent scholarly record includes investigations involving antiseizure medicines, drug interactions, and neurological models. These studies connect clinical neurology with pharmacological questions concerning treatment combinations and biological responses in experimental research settings. [1] [2]

Research Profile

Sibel Ozdemir’s documented research profile centers on neurology and pharmacology, with publications involving antiseizure therapy, experimental seizure models, and medication interactions. PubMed records identify her ORCID as 0009-0003-4671-0964 and associate recent work with Yunus Emre State Hospital. The available evidence supports a clinically oriented pharmacological research profile in clinical practice. [1]

Research Contributions

Sibel Ozdemir contributes to research examining pharmacological effects in neurological conditions. A 2026 study evaluated clopidogrel alongside valproic acid and levetiracetam in a pentylenetetrazol-induced seizure model, while another study examined differential effects of valproic acid and levetiracetam on freezing behavior. These studies address medication efficacy and drug interactions in pharmacology. [1] [2]

Publications

Sibel Ozdemir is listed as an author on publications concerning antiseizure pharmacology and neurological experimental models. Her 2026 International Journal of Molecular Sciences article investigated clopidogrel with valproic acid and levetiracetam, while a 2026 Journal of Biotechnology and Strategic Health Research article examined valproic acid and levetiracetam effects in rats. [1] [2]

Research Impact

Sibel Ozdemir’s research has potential relevance to pharmacological decision-making by investigating how neurological medicines behave in experimental combinations. The documented studies provide evidence about antiseizure efficacy and medication interactions, while their experimental designs also illustrate translational questions that may require further clinical investigation before broader conclusions are drawn. [1] [2]

Award Suitability

Sibel Ozdemir’s publication activity aligns with an Innovative Research Award profile through its focus on pharmacological questions in neurological research and experimental models. The publications demonstrate investigation of drug combinations and antiseizure effects. Award recognition should consider originality, methodological contribution, publication record, and relevance of the submitted research evidence overall. [1] [2]

Conclusion

Sibel Ozdemir’s available scholarly record presents a research trajectory connecting clinical neurology with pharmacology and experimental seizure research. Her recent publications provide documented evidence of work on antiseizure medicines and drug interactions. Continued publication, independent validation, and clinical translation would further clarify the broader significance of these research contributions today. [1] [2]

References

    1. Özdemir, S., Bolayır, E., & Şahin İnan, Z. D. (2026). Effects of Clopidogrel on the Anticonvulsant Efficacy of Valproic Acid and Levetiracetam in a PTZ-Induced Seizure Model. International Journal of Molecular Sciences, 27(14), 6415.
      https://doi.org/10.3390/ijms27146415
    2. Gürkan, İ. M., Demir Cevizlidere, B., Çalişkan, S., Özdemir, S., & Özdemir, H. (2026). Effects of nano-hydroxyapatite-coated PRF on gingiva-derived mesenchymal stem cells: In vitro study. International Journal of Molecular Sciences, 27(13), 5736.
      https://doi.org/10.3390/ijms27135736
    3. ORCID. (n.d.). ORCID record: Sibel Ozdemir, ORCID 0009-0003-4671-0964.
      https://orcid.org/0009-0003-4671-0964
    4. Elsevier. (n.d.). Scopus author details: Sibel Ozdemir, Author ID 60749146700. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=60749146700

Siyu Chen | Pharmacology | Best Researcher Award

Published on by Health Scientists

 Prof. Siyu Chen | Pharmacology | Best Researcher Award

Professor | China Pharmaceutical University | China

Dr. Chen Siyu currently serves as the Deputy Director of the Department of Biochemistry at the School of Life Sciences and Technology, China Pharmaceutical University, where he is also a Professor, Doctoral Supervisor, and Chief Young Scientist of the National Key Research and Development Program. He obtained his academic training in biochemistry and molecular biology, cultivating a strong foundation in metabolic and biochemical sciences. Dr. Chen’s research primarily focuses on Target Discovery and Intervention Strategies for Metabolic Diseases, aiming to elucidate molecular mechanisms and identify novel therapeutic targets for metabolic regulation. He has published extensively as first or corresponding author in leading international journals such as Advanced Science, Nature Communications, and Gut Microbes, with his work widely cited by peers. His innovative research has led to the granting of national patents and multiple ongoing patent applications. Dr. Chen has successfully led major research projects under national and provincial funding programs, including the National Key R&D Program for Young Scientists, the National Natural Science Foundation for Young Scientists, and the Jiangsu Province Excellent Youth Fund. Recognized for his scholarly excellence, he received the Outstanding Doctoral Dissertation Award of Jiangsu Province. In addition to his research, Dr. Chen contributes actively to the academic community as a Young Member of the Metabolism Committee of the Chinese Society of Biochemistry, Director of the Jiangsu Society of Developmental Biology, and Editorial Board Member of Journal of China Pharmaceutical University and Progress in Biochemistry and Biophysics. He also serves as a Guest Editor for Frontiers in Endocrinology and a regular reviewer for leading journals including Journal of Hepatology and ACS Nano. He has 1616 citations from 60 documents with an h-index of 24.

Profiles: Scopus | ORCID

Featured Publications

1. Photosensitive biomimetic nanomedicine-mediated recombination of adipose microenvironments for antiobesity therapy. (2025). Advanced Materials.

2. Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity. (2025). Bioengineering and Translational Medicine.

3. Blue light-driven cell cycle arrest in thyroid cancer via Retinal-OPN3 complex. (2024). Cell Communication and Signaling.

4. Luteolin detoxifies DEHP and prevents liver injury by degrading Uroc1 protein in mice. (2024). EMBO Molecular Medicine.

5. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. (2024). Phytomedicine.